Slc6a11, also known as GAT3, is a gene encoding a sodium-and chloride-dependent GABA transporter. It belongs to the solute carrier 6 (SLC6) family of sodium-dependent transporters. GABA transporters play a crucial role in maintaining the homeostasis of γ-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the central nervous system (CNS). By regulating extracellular GABA levels, Slc6a11 is involved in various neural functions and associated pathways, which are of great biological importance [4,6].

Regarding its role in diseases, a meta-analysis showed that the SLC6A11 rs2304725 polymorphism was not significantly correlated with drug-resistant epilepsy (DRE) in most models, except for the over-dominant model in a pooled population. Another study found no association between 14 SLC6A11 tagSNPs and DRE in the Chinese Han population. However, in a Korean sample, the SLC6A11 rs4684742 polymorphism was associated with tardive dyskinesia, and gene-gene interactions involving SLC6A11 were found to be related to the development of tardive dyskinesia. Also, whole-genome sequencing analysis identified SLC6A11 as a gene nominally associated with clozapine-induced myocarditis [1,2,3,5].

In conclusion, Slc6a11 is essential for GABA homeostasis in the CNS. Studies on its genetic polymorphisms have provided insights into its potential roles in diseases such as drug-resistant epilepsy, tardive dyskinesia, and clozapine-induced myocarditis. Although more research is needed, understanding Slc6a11's functions and associations with diseases may offer new perspectives for disease diagnosis and treatment.